Target intelligence / Profile preview

WD repeat and FYVE domain-containing protein 3 (WDFY3)

Target
WDFY3
Molecular classification
Other, Autophagy adaptor protein, Protein containing WD40 repeats, Protein with BEACH and FYVE domains
01

Overview

WD repeat and FYVE domain-containing protein 3 (WDFY3) is a large scaffolding and adaptor protein containing WD40 repeats, a BEACH domain, and a C-terminal FYVE domain. It functions as a master adaptor for the selective clearance of protein aggregates (aggrephagy) via the autophagy pathway. WDFY3 interacts with components of the autophagic machinery (such as ATG5, ATG12, ATG16L, SQSTM1/p62, and LC3), linking ubiquitinated cargo and aggregated proteins to autophagic vesicles for degradation. It participates in axonal tract formation throughout the brain and spinal cord, is crucial for proper neuron differentiation and migration, and is involved in mitochondrial homeostasis, including mitophagy and energy regulation in neurons. Mutations in WDFY3 are linked to macrocephaly, intellectual disability, autism spectrum disorders, and other neurodevelopmental phenotypes. There is currently no evidence that WDFY3 is a direct drug target, though its pathway is implicated in disease mechanisms for several neurological and psychiatric disorders.

Other names
ALFYZFYVE25BCHSMCPH18WD repeat and FYVE domain containing 3WDFY3
02

Biological functions

Selective macroautophagy (aggrephagy) and autophagosome-lysosome fusionMitochondrial quality control and mitophagyBrain and central nervous system developmentAxon tract formation and neuron differentiationResponse to axon guidance cuesCytoskeleton remodelingRegulation of Wnt signaling by removal of DVL3 aggregatesFatty acid β-oxidation control during neural stem cell self-renewal
03

Disease associations

Neurodevelopmental disordersMacrocephaly/microcephaly syndromesGeneral role in neurodegeneration/neurodegenerative diseasePsychiatric disordersOther
04

Biomarkers

Potential biomarker for neurodevelopmental delay, autism spectrum disorder, and intellectual disability when pathogenic variants are detectedNo validated pharmacodynamic biomarkers for drug selection; relevance is primarily genetic diagnostic

Beyond the preview

Go deeper on WD repeat and FYVE domain-containing protein 3 (WDFY3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD repeat and FYVE domain-containing protein 3 (WDFY3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call